Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Tasigna Global Growth in Constant Currencies by Quarter
Tasigna Global Growth in Constant Currencies (% cc) (%)
Novartis Tasigna Global Growth in Constant Currencies: -37.0% in Q3 2026, up 11.0 pts from a year earlier.
Latest, Q3 2026
-37.0%
Period ended Sep 30, 2026
Change on a year earlier
+11.0 pts
-48.0% in Q3 2025
History
27 quarters
Since Q4 2018
Sources
27
Documents cited below
Where the Q3 2026 figure comes from
“|| Tasigna 4 | 141 | 221 | – 36 | – 37”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K & Form 20-F.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Novartis Tasigna Global Growth in Constant Currencies (%), quarterly Q4 2018–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-tasigna-yoy-cc-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.